Table I.
Lymphocyte apoptosis using FITC-labeled caspase-3 antibody
| No LPS | LPS | LPS/APC | ||
|---|---|---|---|---|
| Spleen tissue | ||||
| T lymphocytes | CD4+ | 0.97 ± 0.21 | 4.98 ± 0.74*** | 3.45 ± 0.54 |
| CD8+ | 1.03 ± 0.21 | 9.18 ± 1.44*** | 7.21 ± 2.3 | |
| B lymphocytes | B220+ | 0.83 ± 0.32 | 4.8 ± 0.82*** | 3.07 ± 1.32 |
| Granulocytes | GR1+ | 0.27 ± 0.21 | 1.61 ± 0.95* | 2.08 ± 0.84 |
| Peripheral blood | ||||
| T lymphocytes | CD4+ | 0.3 ± 0.2 | 8.19 ± 1.67*** | 5.61 ± 1.94 |
| CD8+ | 0.46 ± 0.3 | 9.14 ± 9.42* | 8.97 ± 7.62 | |
| B lymphocytes | B220+ | 0.6 ± 0.33 | 19.4 ± 11.7* | 9.72 ± 9.68 |
| Granulocytes | GR1+ | 0.01 ± 0.01 | 0.24 ± 0.29* | 0.3 ± 0.2 |
All collections were performed 24 h after LPS challenge and APC treatment . *, P ≤ 0.05; and ***, P ≤ 0.001 compared with PBS control mice using the Student's t test.